Literature DB >> 23571545

Severe skin toxicity in pediatric oncology patients treated with voriconazole and concomitant methotrexate.

Johan G C van Hasselt1, Natasha K A van Eijkelenburg, Alwin D R Huitema, Jan H M Schellens, Antoinette Y N Schouten-van Meeteren.   

Abstract

We report the occurrence of skin toxicities in pediatric oncology patients on concomitant treatment with voriconazole and methotrexate (MTX). Of 23 patients who received this combination, 11 patients suffered from cheilitis and/or photosensitivity. In contrast, only in 1 of 9 patients who received voriconazole without MTX was photosensitivity observed. A mechanism of action was not able to be identified. We describe two cases with severe skin toxicities. Caution is warranted when using voriconazole and concomitant MTX.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23571545      PMCID： PMC3716160          DOI： 10.1128/AAC.00068-13

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  18 in total

Review 1.  Severe phototoxicity associated with long-term voriconazole treatment.

Authors:  Sabine Vöhringer; Johanna Schrum; Hagen Ott; Peter H Höger
Journal:  J Dtsch Dermatol Ges       Date:  2010-11-03       Impact factor: 5.584

2.  Methotrexate and the photodermatitis reactivation reaction: a case report and review of the literature.

Authors:  A J Khan; A A Marghoob; A E Prestia; I J Spector
Journal:  Cutis       Date:  2000-11

3.  Acral erythema in children receiving high-dose methotrexate.

Authors:  F Millot; F Auriol; P Brecheteau; F Guilhot
Journal:  Pediatr Dermatol       Date:  1999 Sep-Oct       Impact factor: 1.588

4.  Muco-cutaneous retinoid-effects and facial erythema related to the novel triazole antifungal agent voriconazole.

Authors:  D W Denning; C E Griffiths
Journal:  Clin Exp Dermatol       Date:  2001-11       Impact factor: 3.470

Review 5.  The clinical pharmacology of methotrexate.

Authors:  J H Schornagel; J G McVie
Journal:  Cancer Treat Rev       Date:  1983-03       Impact factor: 12.111

6.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

7.  Systemic methotrexate exposure is greater after intrathecal than after oral administration.

Authors:  Bruce C Bostrom; Gary R Erdmann; Barton A Kamen
Journal:  J Pediatr Hematol Oncol       Date:  2003-02       Impact factor: 1.289

Review 8.  Voriconazole.

Authors:  LilyAnn Jeu; Frank J Piacenti; Aleksandr G Lyakhovetskiy; Horatio B Fung
Journal:  Clin Ther       Date:  2003-05       Impact factor: 3.393

9.  Methotrexate-induced necrolysis.

Authors:  K M Reed; A J Sober
Journal:  J Am Acad Dermatol       Date:  1983-05       Impact factor: 11.527

10.  Two patterns of skin ulceration induced by methotrexate in patients with psoriasis.

Authors:  C M Lawrence; M G Dahl
Journal:  J Am Acad Dermatol       Date:  1984-12       Impact factor: 11.527
View more
  1 in total

Review 1.  Pediatric Invasive Aspergillosis.

Authors:  Rachel L Wattier; Lynn Ramirez-Avila
Journal:  J Fungi (Basel)       Date:  2016-06-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.